Status
Conditions
Treatments
About
To determine whether armodafinil is more effective than placebo in reducing fatigue.
Full description
Aims will be analyzed separately as stratified by treatment arm (chemotherapy treatment arm vs. post-treatment remission arm).
Primary Objective:
Secondary Objectives:
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for both arms:
Inclusion criteria for patients undergoing R-CHOP chemotherapy:
Inclusion criteria for patients in remission following chemotherapy and/or radiotherapy:
May have received one prior regimen of chemotherapy and/or radiotherapy
Adequate response to upfront chemotherapy and/or radiotherapy
Indolent lymphomas - must have achieved a partial or complete response with no immediate plans for further treatment
Aggressive lymphomas - must have achieved a complete response:
Exclusion Criteria for both arms:
Primary purpose
Allocation
Interventional model
Masking
0 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal